AgingResearch.NewsJoin free

Levomepromazine

Intervention

1 paper1 finding

PubChem 72287ChEBI 6838

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funder: Novo Nordisk Fonden
  • Humans1

Associations

1

Major adverse cardiovascular events

upin humans1

1 study

  1. Levomepromazine raises the risk of major adverse cardiovascular events in humans (IRR 3.80, 95% CI 3.43 to 4.21).

    “incidence rate ratios of major adverse cardiovascular events were higher with use of levomepromazine (3.80, 95% CI 3.43 to 4.21)”

    Humanscompared with risperidone, first 30 days of treatment30 days

    Association of Selected Antipsychotic Agents With Major Adverse Cardiovascular Events and Noncardiovascular Mortality in Elderly Persons

    Journal of the American Heart Association1 Sep 2015

Latest

Related